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Objective: To study the actual controlled ovarian stimulation (COS) management in
women with suboptimal response, comparing clinical outcomes to the gonadotropins
consume, considering potential role of luteinizing hormone (LH) addition to
follicle-stimulating hormone (FSH).
Design: Monocentric, observational, retrospective, real-world, clinical trial on fresh
intra-cytoplasmic sperm injection (ICSI) cycles retrieving from 1 to 9 oocytes, performed
at Humanitas Fertility Center from January 1st, 2012 to December 31st, 2015.
Methods: COS protocols provided gonadotropin releasing-hormone (GnRH) agonist
long, flare-up, short and antagonist. Both recombinant and urinary FSH were used
for COS and LH was added according to the clinical practice. ICSI outcomes
considered were: gonadotropins dosages; total, mature, injected and frozen oocytes;
cumulative, transferred and frozen embryos; implantation rate; pregnancy, delivery and
miscarriage rates. Outcomes were compared according to the gonadotropin regimen
used during COS.
Results: Our cohort showed 20.8% of low responders, defined as 1–3 oocytes retrieved
and 79.2% of “suboptimal” responders, defined as 4–9 oocytes retrieved. According
to recent POSEIDON stratification, cycles were divided in group 1 (6.9%), 2 (19.8%),
3 (11.7%), and 4 (61.5%). The cohort was divided in 3 groups, according to the
gonadotropin’s regimen. Women treated with FSH plus LH showed worst prognostic
factors, in terms of age, basal FSH, AMH, and AFC. This difference was evident in
suboptimal responders, whereas only AMH and AFC were different among treatment
groups in low responders. Although a different result, in terms of oocytes and embryos
detected, major ICSI outcomes (i.e., pregnancy and delivery rates) were similar among
groups of COS treatment. Outcomeswere significantly different among Poseidon groups.
Implantation, pregnancy and delivery rates were significantly higher in Poseidon group 1
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and progressively declined in other POSEIDON groups, reaching the worst percentage
in group 4.
Conclusions: In clinical practice, women with worst prognosis factors are generally
treated with a combination of LH and FSH. Despite low prognosis women showed a
reduced number of oocytes retrieved, the final ICSI outcome, in terms of pregnancy,
is similarly among treatment group. This result suggests that the LH addition to FSH
during COS could improve the quality of oocytes retrieved, balancing those differences
that are evident at baseline.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT03290911
Keywords: FSH, LH, ICSI, suboptimal responders, POSEIDON
INTRODUCTION
The number of couples seeking help in assisted reproductive
technologies (ART) is progressively increasing and about 1.5
million cycles are currently performed every year (1). ART
starts with a controlled ovarian stimulation (COS) phase, in
which the ovary is exogenously stimulated with gonadotropins
at producing the largest number of oocytes to be used in
embryo development. During COS, follicle stimulating hormone
(FSH), human menopausal gonadotropin (hMG) and luteinizing
hormone (LH) are variably used. However, a significant inter-
and intra-individual different response to COS is largely
demonstrated so far and the research practice is focused on the
way to optimize ovarian response. In this improving process,
two main challenges remain to be clarified nowadays. First,
how women who poorly respond to COS could be identified?
The first poor responders definition dates back to 1983 (2),
although only in 2011 the first realistic attempt to define poor
responders have been made by the scientific community of
the European society of human reproduction and embryology
(ESHRE) (3). Using this definition, poor responder women show
at least two of the following criteria: (i) advanced age (>40 years),
(ii) previous poor ovarian response (<3 oocytes retrieved), (iii)
abnormal reserve test, detected as antral follicle count (AFC)
< 5–7 or anti-Mullerian hormone (AMH) <0.5–1.1 ng/mL (3).
However, this classification fails to define all patients who
experience poor response to ovarian stimulation. Recently, a new
classification of low ovarian response has been proposed. Four
subgroups have been identified considering quantitative and
qualitative parameters, such as age, antral follicle count (AFC),
and anti-Müllerian hormone (AMH) and ovarian response to
previous stimulation cycle was performed, defined as a number
of retrieved oocytes lower than 9 (4). These criteria could assist
the clinician in the women classification, although they are still
not useful to define the best COS treatment.
The second main challenge in ART is the appropriate
gonadotropins stimulation needs to be used (5, 6). All COS
protocols provide the exogenous FSH administration. Is FSH
alone enough to induce multiple follicle development or a
gonadotropins combination could improve the final outcome?
Although wide consensus is reached about the tailored protocol,
there is currently a lack of consensus on what represents the
gold standard gonadotropins combination to COS. Indeed, COS
schemes remain mainly empirical and a personalized medicine
is still advocated in this setting (7). Best practices suggest the
use 150–300 IU of gonadotropins daily, but no more than 450
IU daily, for a total of 9–10 days (8). These doses are generally
applied considering the women expected response, using an
average dosage of 150 IU for those younger and higher doses
in women who are older or who are expected to have a poorer
response. However, such approaches show poor clinical results
and the ideal COS protocol is still under debate.
In the literature, a wide number of clinical trials evaluated the
efficacy of gonadotropin combinations in COS. However, strong
evidence in favor or contrast to gonadotropins combination is
not reached so far (9). The analysis of large databases of infertile
population could be useful to update the specification of the
“best clinical practice” in ART. With this in mind, considering
that large population based cohorts demonstrated that an oocyte
yield of 10–15 oocytes in all age groups resulted in the most
optimal live birth rate in fresh cycles (10), we decided to
focus on women with low ovarian response according to recent
diagnostic stratification (i.e., 9 oocytes retrieved). Thus, a real-
world trial based on a large database is designed to collect data
from the standard clinical practice in ART center in which all
gonadotropins preparations were used alone or in combination.
The main aim of this study is to analyse the actual COS
management in women with not optimal response, comparing
clinical outcomes to the gonadotropins consume.
MATERIALS AND METHODS
Study Design
A monocentric, observational, retrospective, real-world, clinical
trial was performed evaluating all ART cycles performed at
the Humanitas Fertility Center from January 1st, 2012 and
December 31st, 2015. All fresh cycles of intra-cytoplasmic sperm
injection (ICSI), retrieving 1–9 oocytes were enrolled. Overall,
this study enrolled women with low ovarian response, according
to Patient-Oriented Strategies Encompassing IndividualizeD
Oocyte Number (POSEIDON) stratification system (4, 11–13).
Only ICSI cycles were included in the analyses considering that
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only in this ART methodology information on oocytes quality
have been recorded. Moreover, inclusion criteria provided an
age ≤44 years and a body mass index (BMI) between 18 and
27 kg/m2. The following exclusion criteria were considered: (i)
age > 44 years, (ii) number of oocytes retrieved > 10 or <1 or
cycles suspended before retrieval, (iii) abnormal uterine cavity,
(iv) endometriosis III-IV stage or adenomyosis, (v) testicular
sperms, and (vi) PGT (Preimplantation Genetic Testing). Only
fresh cycles were considered and pregnancies from frozen cycles
were excluded from the analysis.
The study was approved by the Independent Ethical
Committee of the Humanitas Institutional Clinic (Milan,
Italy) (Trial registration number: NCT03290911). Informed
and written consent was obtained from each patient after full
explanation of the purpose and nature of all procedures used.
COS Protocol
The COS protocol provided the use of recombinant FSH
(rFSH), hMG or rFSH + recombinant LH (rFSH + rLH). The
gonadotropin starting dose was determined according to ovarian
reserve parameters, such as AMH, AFC, and BMI.
COS was performed using four different protocols: GnRH
agonist long protocol; GnRH agonist short protocol; GnRH
antagonist protocol; Flare-up GnRH agonist protocol. Most
of antagonist COS starts with the use of combined oral
contraceptives pretreatment.
Long GnRH agonist protocol was based on the administration
of daily leuprorelin (Enantone die, Takeda, Italy) or Triptorelin
Depot (3.75mg IM, Decapeptyl R©, Ipsen, Milan, Italy) on day
21 of the previous luteal phase of the stimulation cycle. When
pituitary desensitization was achieved (14 days after the initiation
of GnRH agonist), as evidenced by the absence of ovarian follicles
>5mm and endometrial thickness <5.4mm on transvaginal
ultrasound examination, gonadotropin stimulation was initiated.
In short GnRH agonist protocol the agonist (Leuprolin 0.1
mg/day) is administered from day 21 of the previous cycled
and induction from day 1 or 2 of the cycle (day 1 being the
start of the menstrual bleed) reducing the agonist dose to 0.05
mg/day and continuing with stimulation until the day of HCG
administration. In the GnRH antagonist protocol, the first day
of women spontaneous menstrual cycle or a withdrawal bleeding
after receiving a low dose oral contraceptive, gonadotropin
stimulation was initiated and when the leading follicle reached
13–14mm in mean diameter, and/or plasma E2 exceeded 400
pg/ml, an injection of 0.25mg of GnRH antagonist (Cetrotide R©,
Merck Serono S.p.A, Rome, Italy; Orgalutran R©, Organon, MSD-
Italy) was administered SC daily until the day of ovulation trigger.
Finally, in the Flare-up GnRH protocol, daily agonist started
on cycle day 1 of the cycle with triptorelin (0.1 mg/day)
and gonadotropins was started according to ovarian reserve
parameter on day 2 of the cycle. A starting variable dose of
gonadotropin (hMG (Meropur R©, Ferring, Milan, Italy) or rFSH
(Puregon R©, MSD-Italy; Gonal-F, Merck Serono S.p.A., Rome,
Italy) with or without the addition of r-LH for the first 4 days
and then an individualized dose was administered according
to the parameters resulting from transvaginal ultrasound and
estradiol and progesterone levels until the day of ovulation
trigger. The protocol of induction and the dose of gonadotropins
administered were tailored on an individual basis according to
patient’s age, serum hormonal levels, and AFC. Transvaginal
ultrasonography, estradiol and progesterone determinations
were performed during COS. When at least three follicles
with a mean diameter >18mm were observed, 250 mcg
of recombinant hCG (Ovitrelle; Merck Serono S.p.A.) was
administered subcutaneously. Oocyte retrieval was performed
transvaginal 36 h after hCG injection. Embryo transfer was
performed day 3–day 5 after oocyte collection. Luteal phase was
supported in all patients with vaginal progesterone (Crinone
8%; Merck Serono S.p.A. or Prometrium; Rottapharm). Serum
hCG was assessed 2 weeks after embryo transfer and then every
48 h until a value over 1,000 mIU was detected and a vaginal
ultrasound was scheduled 4 weeks after the embryo transfer.
Parameters Detected
All anamnestic information was collected, with attention to the
years of infertility and the indication to ART. Baseline women
characteristics were collected after the last menstrual cycle before
ART, such as female age, AFC, FSH, LH, estradiol, TSH, AMH
and inhibin B serum levels. AMH and AFC were evaluated
considering previous statements (14). The ART protocol applied
was registered, considering the GnRH analog used, the FSH and
LH doses used and the duration of the COS protocol. Finally,
considering the ART outcomes, the following outcomes were
considered: oocytes retrieved, oocyte nuclear maturity stage,
injected, frozen and fertilized oocytes, transferred and frozen
embryos. Implantation, pregnancy, live birth, and miscarriage /
ectopic rates were finally collected. The implantation rate was
calculated as the ratio between the number of gestational sacs
identified at this time and the number of embryos transferred.
Clinical pregnancy was defined a pregnancy as visualization
of one or more gestational sacs or definitive clinical signs of
pregnancy. It includes ectopic pregnancy as defined by The
International Committee for Monitoring Assisted Reproductive
Technology (ICMART) and the World Health Organization
(WHO) Revised, Glossary on ART Terminology, 2009 [21].
Miscarriage rate and ectopic pregnancies, per clinical pregnancy,
were defined as the proportion of patients who failed to
continue development before 20 weeks of gestation in all clinical
pregnancies. Live birth was defined as the delivery of a fetus with
signs of life after 20 completed weeks of gestational age.
Statistical Analysis
The entire dataset was first evaluated to select each single couple
treated with ART. These couples represented the entire cohort of
patients evaluated by the study.
Descriptive analyses were performed considering the entire
cohort of patients. Continuous variables distribution was
evaluated with Kolmogorov-Smirnov test. According to the
not normal distribution, continuous variables were compared
with Kruskal Wallis non-parametric test. Post-hoc analyses were
performed by Tukey test. Continuous variables are expressed
as mean ± standard deviation. Categorical variables were
compared using Fisher exact test and they were expressed as
number (percentage). Multiple linear stepwise analyses were
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performed considering implantation rate as dependent variable
and other parameters as independent variables. These analyses
were repeated, considering the following POSEIDON groups:
(1) age <35 years with adequate ovarian reserve (AFC>5 and
AMH>1.2 ng/mL) and 9 oocytes retrieved; (2) age >35 years
with adequate ovarian reserve (AFC>5 and AMH>1.2 ng/mL)
and 9 oocytes retrieved; (3) age <35 years with poor ovarian
reserve (AFC<5 and AMH<1.2 ng/mL); (2) age >35 years with
poor ovarian reserve (AFC<5 and AMH<1.2 ng/mL).
Statistical analysis was performed using the “Statistical
Package for the Social Sciences” software for Macintosh
(version 21.0; SPSS Inc., Chicago, IL). Considering that
multiple hypotheses were tested together, and multiple
analyses were performed, the statistical significance was
evaluated after correction using Bonferroni test. Thus, nine
endpoints were consecutively evaluated, and the p-values
was considered statistically significant when p < 0.0005.
Moreover, considering the real-world data registration considers
both repeated (i.e., multiple cycles performed for the same
couples) and missing data, the missing not at random (MNAR)
approach was used to adjust analyses (15). To this purpose,
the Expectation-Maximization method was applied, creating
a new dataset in which all missing values are estimated by the
maximum likelihood methods (16).
RESULTS
Twelve thousand five hundred and forty-three ART cycles were
performed from January 1st, 2012 and December 31st, 2015 on
9,928 infertile couples. Finally, 4,828 cycles fulfilled inclusion
and exclusion criteria and represented the final cohort evaluated.
Figure 1 showed the study flow chart and reported the reasons
for exclusion (Figure 1).
The mean infertility duration was 4.61 + 7.18 years, with a
mean age of 37.67 + 3.68 years for the female and 40.02 + 5.37
years for the male partner. The mean number oocytes retrieved
was 5.55 + 2.40 (from a minimum 1 to a maximum of 9). The
transfer was suspended in 528 cycles (10.9%), due to sperms
absence in 15 cycles (0.3%), oocytes low quality in 131 (2.7%), no
fertilization in 241 (5.0%), lack of oocyte cleavage in 57 (1.2%),
embryos not developed in 13 (0.3%), OHSS risk in 51 (1.0%),
and complications in 20 (0.4%). Severe OHSS was developed in
4 cycles (0.1%).
The entire cohort showed the 20.8% of low responders (1,006
women who retrieved 1–3 oocytes) and the 79.2% of women with
a “suboptimal” response (3,822 patients who collected from 4 to
9 oocytes). The cohort of ART cycles was divided in the following
3 groups, according to the gonadotropins regimen: (i) group 1:
FSH alone (3,338 cycles, 69.1%); (ii) group 2: hMG alone (678
FIGURE 1 | Study flow chart. *p<0.05.
Frontiers in Endocrinology | www.frontiersin.org 4 May 2019 | Volume 10 | Article 282
Levi-Setti et al. Low Prognosis Women in IVF
cycles, 14.0%); (iii) group 3 FSH combined to LH (812 cycles,
16.8%). Moreover, according to recent patients stratification, the
18.6% (897 women) of women enrolled were below than 35 years
old and the 73.3% (3,538 women) showed low ovarian reserve
parameters, in terms of AFC and AMH. Thus, considering
the POSEIDON stratification, group 1 included 233 patients
(6.9%), group 2 958 (19.8%), group 3 565 (11.7%) and group 4
2,973 (61.5%).
Comparison Among Gonadotropins
Groups
At baseline, a significant difference among groups was detected.
Female age was significantly higher in group 3 compared to
group 1 and 2 (p < 0.001 and p < 0.001, respectively) (Table 1).
Moreover, female age was significantly higher in hMG group
compared to FSH group (p < 0.001; Figure 2). Basal FSH serum
levels were significantly higher in group 3, compared to groups
1 and 2 (p < 0.001 and p < 0.001, respectively) and lower levels
were detected in group 1 compared to 2 (p = 0.001; Figure 3).
Similar trend was detected for AMH and AFC, which were
significantly higher in group 1 and progressively decreased until
group 3 (Figures 4, 5). On the contrary, basal LH did not change
among groups (Table 1). These results, taken together, suggest
that a different clinical approach is generally applied, preferring
the LH addition to FSH when a low response is expected.
The GnRH analog used to induce COS was different
among groups. The GnRH antagonist was generally chosen
when FSH or hMG were used. On the contrary, when the
FSH and LH combination was selected, agonist flare-up and
antagonist protocols were equally used (Table 1). The duration
TABLE 1 | Patients and ART outcomes.
Variable FSH alone hMG FSH+LH p-value
Number of cycles n (%) 3,338 (69.1%) 678 (14.0%) 812 (16.9%) -
Female Age (years) 37.26 ± 3.77 38.49 ± 3.47 38.70 ± 3.12 <0.001
Male Age (years) 39.69 ± 5.40 40.76 ± 5.53 40.74 ± 4.99 <0.001
Basal FSH (IU/L) 7.88 ± 3.16 8.44 ± 3.51 8.91 ± 3.66 <0.001
Basal LH (IU/L) 5.80 ± 7.65 5.19 ± 4.70 5.70 ± 4.81 0.641
AMH (ng/mL) 1.62 ± 1.60 1.11 ± 1.16 0.98 ± 1.06 <0.001
AFC 8.31 ± 5.99 6.45 ± 3.82 5.33 ± 3.09 <0.001
Number of ART cycles n (%) 2.47 ± 1.13 2.32 ± 1.07 1.98 ± 1.02 0.091
Induction protocol n (%) <0.001
Antagonist cycle 1,617 (48.4%) 323 (47.6%) 307 (37.8%)
Agonist flare-up 750 (22.5%) 198 (29.2%) 258 (31.8%)
Agonist long 409 (12.3%) 56 (8.3%) 86 (10.6%)
Agonist short 38 (1.2%) 9 (1.3%) 30 (3.7%)
Induction length (days) 11.57 ± 2.92 11.47 ± 1.87 12.01 ± 3.97 0.123
Total FSH doses (IU) 3,319 ± 1,351 3,573 ± 1,240 3,217 ± 1,033 <0.001
Total LH dose (IU) 0 0 1423 ± 562 <0.001
FSH dose/oocytes ratio 798.88 ± 824.60 935.37 ± 786.48 845.61 ± 795.86 <0.001
Retrieved oocytes 5.78 ± 2.45 5.13 ± 2.17 4.96 ± 2.11 <0.001
MII oocytes 4.32 ± 2.10 3.87 ± 1.91 3.77 ± 1.86 <0.001
MII oocytes/oocytes retrieved 0.75 ± 0.24 0.77 ± 0.24 0.77 ± 0.24 0.042
Injected oocytes 4.21 ± 2.09 3.82 ± 1.92 3.69 ± 1.86 <0.001
Frozen oocytes 0.04 ± 0.46 0.03 ± 0.36 0.03 ± 0.40 0.816
Fertilized oocytes 3.03 ± 1.89 2.73 ± 1.72 2.60 ± 1.65 <0.001
Cumulative embryos 2.15 ± 1.17 2.06 ± 1.11 2.03 ± 1.09 0.009
Transferred embryos 1.84 ± 0.94 1.85 ± 0.96 1.87 ± 0.99 0.785
Frozen embryos 0.32 ± 0.77 0.22 ± 0.61 0.17 ± 0.53 0.054
Implantation rate % 13 ± 28 12 ± 26 11 ± 26 0.252
Biochemical pregnancies n (%) 663 (19.9) 126 (18.6%) 145 (17.9%) 0.353
Deliveries n (%) 477 (14.3%) 90 (13.3%) 102 (12.6%) 0.926
Miscarriages n (%) * 174 (5.2%) 33 (4.9%) 41 (5.0%) 0.954
Miscarriages n (%) ** 174 (26.2%) 33 (26.2%) 41 (28.3%)
Ectopic pregnancies n(%)* 11 (0.3%) 3 (0.4%) 2 (0.2%) 0.960
Ectopic pregnancies n(%)** 11 (1.7%) 3 (2.4%) 2 (1.4%)
Data are expressed as mean ± standard deviation or number (percentage).
* % Considering the total number of cycles.
** % Considering the number of clinical pregnancies.
Bold values, represent statistical significant p-values.
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FIGURE 2 | Female age among groups of patients, divided according to
gonadotropins regimen chosen.
FIGURE 3 | Basal follicle stimulating hormone (FSH) serum levels among
groups of patients, divided according to gonadotropins regimen chosen.
of gonadotropins administration was similar among groups (p=
0.123; Table 1), whereas an obvious difference in gonadotropin
dosages was detected. FSH doses were significantly higher in
group 2 compared to 1 and 3 (p < 0.001 and p < 0.001,
respectively), whereas no FSH dosages differences were seen
between groups 1 and 3 (p = 0.107). This difference translated
in a significant reduction in the FSH dose needed for each oocyte
retrieved (Table 1), comparing group 3 with groups 2 (p< 0.001).
The number of oocytes retrieved was higher in group 1
compared to group 2 and 3 (p < 0.001 and p < 0.001,
respectively) (Table 1 and Figure 6). However, no significant
differences were seen between groups 2 and 3 (p = 0.319),
suggesting that despite the baseline differences between these
two groups, the addition of LH to FSH retrieved a relative
higher oocytes number compared to hMG. Similarly, the
FIGURE 4 | Anti-Mullerian hormone (AMH) among groups of patients, divided
according to gonadotropins regimen chosen. *p<0.05.
FIGURE 5 | Antral follicle count (AFC) among groups of patients, divided
according to gonadotropins regimen chosen. *p<0.05.
number of MII oocytes reflected the total oocytes number,
with a higher retrievement in group 1 compared to groups
2 and 3 (p < 0.001 and p < 0.001) and a similar number
between groups 2 and 3 (p = 0.620). Interestingly, the MII
oocytes on total oocytes retrieved ratio was not different
among groups (Table 1). Again, similar trend was observed
for injected and fertilized oocytes (Table 1). Despite the
differences between group 1 and other groups, the number
of cumulative, transferred and frozen embryos did not differ
among groups (Table 1), suggesting that the addition of LH
improve the oocytes quality and capability to develop embryos.
This hypothesis was further confirmed by the similar results
among groups obtained for implantation, pregnancy and delivery
rates (Table 1).
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FIGURE 6 | Retrieved oocytes among groups of patients, divided according
to gonadotropins regimen chosen.
Comparison Among Patients Stratification
Considering only women with low response (1–3 oocytes
retrieved), despite the different baseline characteristics, all ART
outcomes evaluated did not differ among groups (Table 2).
On the contrary, considering women with a “suboptimal”
response (oocytes retrieved between 4 and 9), the three
groups showed significant differences (Table 3). First, baseline
characteristics (i.e., age, FSH, AMH and AFC) were significantly
impaired in group 3 compared to group 1 and 2 and
in group 2 compared to group 1. Considering the ART
outcomes, the number of total, MII, injected and fertilized
oocytes was significant higher when FSH was used alone
(group 1), compared to hMG (group 2) or FSH plus
LH (group 3), while no differences were seen between
groups 2 and 3. Moreover, other endpoints (i.e., embryos,
implantation, pregnancy and delivery rates) were not different
among groups (Table 3). These results suggest that the LH
addition to FSH reduce the baseline differences among
women obtaining similar outcomes to those women with
better prognosis. These differences were maintained after
analysis statistical adjustment for women age, AFC, AMH
and GnRH protocols used. Finally, multivariate analyses were
not able to identified independent variables able to modifying
independent one.
All ART outcomes were significantly different among
groups after patients stratification (Table 4). Post-hoc analyses
showed better ART outcomes in group 1 compared to other
three groups and group 4 showed lower ART outcomes
compared to others. Accordingly, implantation, pregnancy
and delivery rates were significantly higher in group 1 and
progressively declined among POSEIDON groups, reaching the
worst percentage in group 4 (Table 4). However, the COS
stimulation in these groups was not homogeneous, showing
higher FSH and lower LH doses in women belonged to group
1 (Table 4), confirming the previous suggestion that clinician
usually adapted the gonadotropin stimulation to the women
ovarian reserve.
DISCUSSION
Our study supports the substantial effect of LH addition to
FSH during COS in a large real-world ART setting. Here,
4,828 ICSI cycles performed on women with less or equal than
9 oocytes retrieved have been fully evaluated. Despite these
women are known to poorly respond to COS protocol, baseline
clinical characteristics guide the clinician’s decision about the
best COS approach. Indeed, women with higher age, higher
FSH basal levels, lower AMH serum levels and lower AFC
(representing the 30.9% of the entire cohort) are generally
treated with gonadotropin combination. In particular, the worst
clinical baseline picture, occurring in 16.8% of the cohort, is
preferentially treated with FSH plus LH, instead of hMG (i.e.,
FSH plus hCG). On the contrary, women with a best baseline
clinical picture (the 69.1% of the entire cohort) are treated with
FSH alone. This clinical approach is further confirmed stratifying
patients considering more recent classification, dividing women
according to the number oocytes retrieved and the ovarian
reserve (i.e., AFC and AMH serum levels) (4). However, despite
the unbalance between patients’ baseline characteristics, the final
ART outcomes are similar among the three COS approaches
evaluated. Indeed, FSH alone, hMG or FSH plus LH reached
the same result, in terms of embryos number, implantation,
pregnancy and delivery rates. This is extremely important
considering that the number of oocytes retrieved is an important
prognostic variable for ART success (17, 18). The LH addition
to FSH balances the final ART outcome among groups, despite
the women clinical baseline differences. Interestingly, the use of
hMG is usually chosen for those women with expected results
within FSH alone or FSH-LH combination (14.0%). According,
hMG obtains similar results to other groups, suggesting that the
hCG-LH activity added to FSH during COS can improve the
final ART outcome. However, the use of hMG shows a higher
FSH on oocytes ratio, suggesting that this approach leads to a
higher FSH consume to obtain stimulation like FSH alone or FSH
plus LH.
The beneficial action of LH on COS is particularly evident
dividing women enrolled in two clinical groups: low and
suboptimal responders. Low responders should represent women
with 1–3 oocytes retrieved, whereas suboptimal those with
4–9 oocytes. Indeed, Sunkara et al. established that women
with 4–9 oocytes retrieved result in acceptable live birth rates,
ranging from 15 to 36%, although the level of response
to stimulation which is not ideal (18) Indeed, age-matched
women with 10–15 oocytes retrieved obtain a live birth
rates 20–30% higher (18). When suboptimal responders are
considered, the beneficial LH action is confirmed. Indeed, in
this subgroup, women are treated with FSH alone when the
better outcome is expected, whereas the FSH-LH combination
is preferred when an impaired baseline picture is evident,
such as higher age, FSH basal levels and lower AMH and
AFC. Despite these differences, the LH addition improves the
ART outcome, obtaining similar results in terms of embryos
number, implantation, pregnancy and delivery rates. On the
other hand, low responders, although reduced of number (1,096
women), show a slight baseline difference among groups of
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TABLE 2 | ART outcomes in low responder women.
Variable FSH hMG FSH+LH p-value
Number of cycles n (%) 623 (61.9%) 164 (16.3%) 219 (21.8%)
Female Age (years) 38.00 ± 3.45 38.74 ± 3.35 38.74 ± 2.96 0.002
Male Age (years) 40.01 ± 5.38 41.10 ± 6.45 40.36 ± 4.77 0.070
Basal FSH (IU/L) 9.01 ± 3.97 9.61 ± 3.99 9.57 ± 3.91 0.083
Basal LH (IU/L) 5.36 ± 2.75 5.09 ± 2.05 6.11 ± 2.47 0.019
AMH (ng/mL) ± 1.16 0.69 ± 0.76 0.66 ± 0.82 <0.001
AFC 6.29 ± 4.68 5.58 ± 3.52 4.80 ± 2.44 <0.001
Total FSH doses (IU/L) 3,893 ± 1,375 3,621 ± 1,289 3,269 ± 1,046 <0.001
Total LH dose (IU/L) 0 0 1,484 ± 575 <0.001
FSH dose/oocytes ratio 1,944 ± 1,276 1,847 ± 1,069 1,555 ± 825 <0.001
Oocytes retrieved 2.36 ± 0.73 2.27 ± 0.74 2.37 ± 0.69 0.327
MII oocytes 1.78 ± 0.91 1.84 ± 0.85 1.86 ± 0.86 0.481
MII oocytes/oocytes retrieved 0.75 ± 0.32 0.80 ± 0.29 0.78 ± 0.30 0.099
Injected oocytes 1.76 ± 0.94 1.81 ± 0.88 1.84 ± 0.87 0.488
Frozen oocytes 0.01 ± 0.17 0.02 ± 0.17 0 0.495
Fertilized oocytes 1.31 ± 0.94 1.20 ± 0.90 1.41 ± 0.89 0.075
Cumulative embryos 1.25 ± 0.91 1.16 ± 0.88 1.34 ± 0.86 0.149
Transferred embryos 1.22 ± 0.90 1.212 ± 0.87 1.32 ± 0.87 0.084
Frozen embryos 0.03 ± 0.22 0.04 ± 0.23 0.01 ± 0.12 0.418
Implantation rate 10.05 ± 27.00 9.38 ± 25.08 13.48 ± 29.68 0.305
Biochemical pregnancies n (%) 65 (10.4%) 17 (10.4%) 35 (16.0%) 0.186
Deliveries n (%) 40 (6.4%) 11 (6.7%) 21 (9.6%) 0.948
Miscarriage n (%) * 24 (3.8%) 6 (3.7%) 14 (6.4%) 0.921
Miscarriage n (%)** 24 (36.9%) 6 (35.3%) 14 (40.0%)
Ectopic pregnancies n (%)* 1 (0.2%) 0 (0%) 0 (0%) 0.978
Ectopic pregnancies n (%)** 1 (1.5%) 0 (0%) 0 (0%)
Data are expressed as mean ± standard deviation or number (percentage).
* % Considering the total number of cycles.
** % Considering the number of clinical pregnancies.
Bold values, represent statistical significant p-values.
COS approaches, only in terms of AMH and AFC. According
to the reduced baseline difference, the final ART outcome
remains similar among groups. However, no differences are
observed also in terms of oocytes number and quality. Thus,
it is probable that the LH addition improves the entire COS
process, reducing the differences among women according to
the baseline characteristics. In this context, a further evaluation
of potential single nucleotide polymorphisms (SNP) effect
on ART outcomes must be considered. Indeed, several trials
suggested so far that gonadotropin effect during ART Could be
modulated by SNP on gonadotropin and gonadotropin-receptor
genes (19–25).
Nowadays in ART it is well known that COS schemes
should be personalized to each woman to ensure the highest
chance of live birth rate (7, 26). Several models have been
developed with the aim at predicting outcomes for the infertile
patient and at tailoring gonadotropins stimulation (27–29).
These models involve similar, well-established predictors, such as
female age, duration of infertility, number of previous successful
or unsuccessful ART cycles, pregnancy history and whether
infertility was caused by tubal pathology. However, they still
need external validation and they are not routinely clinically
applied (30, 31). These models are well designed on poor
responders, although a well-standardized approach remains far
to be completely elucidated (32, 33). However, no specific
large datasets are available to build predictive models for poor
responder patients. This is the first real-world evaluation of more
than twelve thousandART cycles. This paper is a perfect snapshot
of population who typically attends ART centers: woman average
age is higher than 37 years and the entire cohort showed
the 38.5% of patients with a not-optimal response to ovarian
stimulation (≤9 oocytes retrieved). Thus, alongside the wide
number of women enrolled, our trial gives an interesting focus
on the actual COS approach in clinical practice.
A large number of clinical trials and meta-analyses have been
performed at comparing different gonadotropins combinations
in terms of COS outcome (34–40). These publications focused
on a wide range of heterogeneous studies, evaluating different
endpoints, setting and patient characteristics. Recently, a more-
comprehensive meta-analysis on FSH plus LH during COS has
been performed, including 70 clinical trials and detecting a clear
effect of LH on the final ART outcomes (41). Whether FSH alone
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TABLE 3 | ART outcomes in “suboptimal” responder women.
Variable FSH hMG FSH+LH p-value
Number of cycles n (%) 2,715 (71.0%) 514 (13.4%) 593 (15.5%)
Female Age (years) 37.09 ± 3.84 38.41 ± 3.50 38.68 ± 3.18 <0.001
Male Age (years) 39.62 ± 5.40 40.65 ± 5.20 40.88 ± 45.07 <0.001
Basal FSH (IU/L) 7.62 ± 2.88 8.07 ± 3.26 8.67 ± 3.53 <0.001
Basal LH (IU/L) 5.90 ± 9.53 5.22 ± 5.24 5.55 ± 4.04 0.674
AMH (ng/mL) 1.77 ± 1.66 1.25 ± 1.23 1.10 ± 1.12 <0.001
AFC 8.74 ± 6.15 6.73 ± 3.88 5.84 ± 3.28 <0.001
Total FSH doses (IU/L) 3,187 ± 1,312 3,559 ± 1,225 3,197 ± 1,028 <0.001
Total LH dose (IU/L) 0 0 1,401 ± 556 <0.001
FSH dose/oocytes ratio 536 ± 303 644 ± 319 583 ± 249 <0.001
Oocytes retrieved 6.56 ± 1.67 6.04 ± 1.62 5.92 ± 1.59 <0.001
MII oocytes 4.90 ± 1.85 4.51 ± 1.69 4.47 ± 1.63 <0.001
MII oocytes/oocytes retrieved 0.75 ± 0.21 0.75 ± 0.22 0.76 ± 0.21 0.314
Injected oocytes 4.77 ± 1.86 4.46 ± 1.71 4.37 ± 1.65 <0.001
Frozen oocytes 0.05 ± 0.50 0.04 ± 0.40 0.05 ± 0.47 0.844
Fertilized oocytes 3.42 ± 1.83 3.22 ± 1.63 3.04 ± 1.65 <0.001
Cumulative embryos 2.36 ± 1.12 2.35 ± 1.02 2.29 ± 1.06 0.316
Transferred embryos 1.99 ± 0.89 2.09 ± 0.87 2.07 ± 0.95 0.017
Frozen embryos 0.38 ± 0.83 0.27 ± 0.67 0.22 ± 0.60 0.072
Implantation rate 13.89 ± 27.69 12.97 ± 26.70 10.86 ± 24.33 0.060
Biochemical pregnancies n (%) 598 (22.0%) 109 (21.2%) 110 (18.5%) 0.170
Deliveries n (%) 437 (16.1%) 79 (15.4%) 81 (13.7%) 0.981
Miscarriage n (%)* 150 (5.5%) 27 (5.2%) 27 (4.5%) 0.962
Miscarriage n (%)** 150 (25.1%) 27 (24.8%) 27 (24.5%)
Ectopic pregnancies n (%)* 10 (0.4%) 3 (0.6%) 2 (0.3%) 0.941
Ectopic pregnancies n (%)** 10 (1.7%) 3 (2.7%) 2 (1.8%)
Data are expressed as mean ± standard deviation or number (percentage).
* % Considering the total number of cycles.
** % Considering the number of clinical pregnancies.
Bold values, represent statistical significant p-values.
TABLE 4 | ART outcomes women divided according to POSEIDON stratification.
Variable Group 1 Group 2 Group 3 Group 4 p-value
Total FSH doses (IU/L) 2,182 ± 998 2,882 ± 1,127 3,282 ± 1,380 3,624 ± 1,329 <0.001
Total LH dose (IU/L) 50 ± 236 137 ± 406 219 ± 545 351 ± 654 <0.001
Oocytes retrieved 6.68 ± 1.91 6.38 ± 2.09 5.69 ± 2.22 5.13 ± 2.21 <0.001
FSH dose/oocytes ratio 380 ± 280 561 ± 520 779 ± 709 970 ± 874 <0.001
MII oocytes 5.11 ± 2.05 4.87 ± 2.02 4.21 ± 2.03 3.83 ± 1.97 <0.001
MII oocytes/oocytes retrieved 0.76 ± 0.22 0.76 ± 0.21 0.74 ± 0.23 0.75 ± 0.25 0.187
Injected oocytes 5.01 ± 2.01 4.74 ± 2.01 4.09 ± 2.02 3.74 ± 1.96 <0.001
Frozen oocytes 0.01 ± 0.17 0.07 ± 0.62 0.03 ± 0.39 0.03 ± 0.39 0.097
Fertilized oocytes 3.64 ± 1.92 3.46 ± 1.89 2.95 ± 1.89 2.65 ± 1.73 <0.001
Cumulative embryos 2.31 ± 1.14 2.36 ± 1.20 2.00 ± 1.15 2.05 ± 1.12 <0.001
Transferred embryos 1.69 ± 0.63 1.96 ± 0.99 1.59 ± 0.71 1.88 ± 0.99 <0.001
Frozen embryos 0.63 ± 1.00 0.40 ± 0.90 0.42 ± 0.85 0.17 ± 0.54 <0.001
Implantation rate 20.64 ± 35.17 13.03 ± 26.19 19.70 ± 26.19 10.57 ± 24.48 <0.001
Biochemical pregnancies n (%) 91 (30.1%) 199 (23.9%) 144 (29.1%) 500 (19.2%) <0.001
Deliveries n (%) 82 (27.1%) 136 (16.3%) 119 (24.0%) 334 (12.8%) <0.001
Miscarriage n (%)* 8 (2.6%) 59 (7.1%) 23 (4.6%) 158 (6.1%) <0.001
Miscarriage n (%)** 8 (8.8%) 59 (29.6%) 23 (16.0%) 158 (31.6%)
Ectopic pregnancies n (%)* 1 (0.3%) 4 (0.5%) 2 (0.4%) 9 (0.3%) <0.001
Ectopic pregnancies n (%)** 1 (1.1%) 4 (2.0%) 2 (1.4%) 9 (1.8%)
Data are expressed as mean ± standard deviation or number (percentage).
* % Considering the total number of cycles.
** % Considering the number of clinical pregnancies.
Bold values, represent statistical significant p-values.
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obtains higher oocyte number, the FSH-LH combination leads
to a higher pregnancy rate (41). Thus, the LH addition seems
to increase the selective pressure on follicular selection exerted
by the two gonadotropins together, improving oocyte quality.
Here, we support these previous results in a real-world setting.
Indeed, our results confirm in a clinical setting the LH molecular
action widely demonstrated in the literature. Indeed, through
the specific receptor binding, LH leads to highest activation of
ERK1/2 and AKT-pathway and a final proliferative and anti-
apoptotic signal (42, 43). LH exerts a proliferative action at
molecular level, leading to a better ART outcome. This study
shows three main limitations. First, this study was retrospectively
designed, thus possible selection and performed biases should
be considered. Indeed, clinical trials should provide an a priori
study design, which help in the selection of patients, limiting
the inter- and intra-individual differences. Second, the groups
of treatment show a significant baseline differences, in terms of
those parameters widely associated to the final ART outcomes.
Thus, the groups are not completely comparable at baseline and
consequently a clear advantage to one treatment to another is not
clearly demonstrated. Third, the gonadotropin administration is
not standardized in each group, but each woman was treated with
a tailored therapy.
In conclusion, in our work, a deep and accurate description
of ovarian response to COS in a large population of women
undergoing ART is performed. Here, more than 4,000 cycles
of women with sub-optimal response are detected, defined as
those women who retrieve from 1 to 9 oocytes. Using this large
database, for the first time a beneficial effect of LH addition to
FSH during COS raises from the clinical practice. In particular,
the gonadotropin combination is usually preferred when
impaired clinical features are evident at baseline. This combined
approach can reduce these differences, reaching similar ART
outcomes. The results have been analyzed comparing both COS
approaches and POSEIDN stratification. This latter shows clearly
differences among POSEIDON groups.
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